SUBSEQUENT EVENTS (Details Narrative) - USD ($)									3 Months Ended		12 Months Ended
	Dec. 31, 2024	Aug. 19, 2024	May 01, 2024	Jan. 01, 2024	Dec. 31, 2023	Jan. 01, 2023	Dec. 31, 2022	Jan. 01, 2022	Mar. 31, 2024	Dec. 31, 2023	Dec. 31, 2023	Dec. 31, 2022	Oct. 25, 2024	Nov. 15, 2020	Oct. 05, 2017
Subsequent Event [Line Items]
Stock Issued During Period, Value, Conversion of Convertible Securities											$ 316,588	$ 1,520,381
Paid-in-Kind Interest											$ 51,588	$ 53,371
Common Stock, Shares, Outstanding					144,642,333		123,345,985			144,642,333	144,642,333	123,345,985
Preferred Stock, Par or Stated Value Per Share					$ 0.001		$ 0.001			$ 0.001	$ 0.001	$ 0.001
Pharmalectin, Inc. [Member]
Subsequent Event [Line Items]
Common Stock, Shares, Outstanding					29,410,000					29,410,000	29,410,000
Preferred Stock, Par or Stated Value Per Share															$ 0.0001
Pharmalectin, Inc. [Member] | Joint Venture Aggrement [Member]
Subsequent Event [Line Items]
Common Stock, Shares, Outstanding														15,000,000
Percentage of oustanding shares														17.50%
Stock Redeemed or Called During Period, Shares		14,410,000
Percentage of shares exchanged		49.00%
Common Stock [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Value, Conversion of Convertible Securities										$ 30,000	$ 2,435	$ 6,081
Stock Issued During Period, Shares, Conversion of Convertible Securities											2,435,291	6,081,484
Stock Issued During Period, Shares, New Issues					144,642,333	123,345,985	123,345,985	110,840,998			534,815	354,000
Subsequent Event [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Value, Conversion of Convertible Securities									$ 1,263,562
Paid-in-Kind Interest									$ 163,562
Stock Issued During Period, Shares, New Issues		8,973,405
Accrued Salaries		$ 353,840
Subsequent Event [Member] | NDPD Pharma Inc [Member]
Subsequent Event [Line Items]
Business Acquisition, Percentage of Voting Interests Acquired													100.00%
Subsequent Event [Member] | Convertible Preferred Stock [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Shares, Conversion of Convertible Securities		28,971,248
Preferred Stock, Par or Stated Value Per Share		$ 0.001
Preferred Stock, Convertible, Terms		5:1 basis, as per the Certificate of Designation dated April 19, 2024
Subsequent Event [Member] | Pharmalectin, Inc. [Member] | Joint Venture Aggrement [Member]
Subsequent Event [Line Items]
Stock Redeemed or Called During Period, Shares		14,410,000
Percentage of shares exchanged		49.00%
Subsequent Event [Member] | Convertible Notes Payable [Member] | Two Thousand Twenty One Holder [Member]
Subsequent Event [Line Items]
Debt Instrument, Unamortized Discount			$ 105,000
Debt Conversion, Description			the conversion price was adjusted to the lower of (i) a fixed price of $
Debt Instrument, Convertible, Conversion Price			$ 0.08
Conversion price, converted			$ 70,000
Subsequent Event [Member] | Common Stock [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Shares, Conversion of Convertible Securities		94,057,658							9,857,092
Stock Issued During Period, Shares, New Issues	86,782,908			144,642,333
Preferred Stock, Convertible, Terms		The Preferred shares can at any time be converted back into shares of Common Stock at a 1:5 basis